Protocol for the New Medicine Service Study: A randomized controlled trial and economic evaluation with qualitative appraisal comparing the effectiveness and cost effectiveness of the New Medicine Service in community pharmacies in England

Trials

Volumn 14, Issue 1, 2013, Pages

  Boyd, Matthew ^a   Waring, Justin ^a   Barber, Nick ^b   Mehta, Rajnikant ^a   Chuter, Antony ^c   Avery, Anthony J ^d   Salema, Nde Eshimuni ^a   Davies, James ^b   Latif, Asam ^a   Tanajewski, Lukasz ^a   Elliott, Rachel A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c Division of Primary Care ^*  (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG SURVEILLANCE PROGRAM; ECONOMIC EVALUATION; HOSPITAL SERVICE; HUMAN; HYPERTENSION; INTERVIEW; LIFE; MEDICAL ETHICS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACIST; PHARMACY; PRESCRIPTION; QUALITATIVE ANALYSIS; QUALITATIVE RESEARCH; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; UNITED KINGDOM;

CLINICAL PROTOCOLS; COMMUNITY PHARMACY SERVICES; COST-BENEFIT ANALYSIS; ENGLAND; ETHICS, MEDICAL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PHARMACISTS; QUALITATIVE RESEARCH; RESEARCH DESIGN;

EID: 84888336806     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-411     Document Type: Article

References (75)

1. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. [see comment]. Med Care 2004, 42:200-209. 10.1097/01.mlr.0000114908.90348.f9, 15076819.
2. World Health Organization Adherence to Long-term Therapies. Evidence for Action 2003, http://whqlibdoc.who.int/publications/2003/9241545992.pdf, World Health Organization.
3. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497. 10.1056/NEJMra050100, 16079372.
4. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, Campbell R. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005, 61(1):133-155. 10.1016/j.socscimed.2004.11.063, 15847968.
5. Elliott RA, Ross-Degnan D, Adams AS, Safran DG, Soumerai SB. Strategies for coping in a complex world: adherence behavior among older adults with chronic illness. J Gen Intern Med 2007, 22(6):805-810. 10.1007/s11606-007-0193-5, 2219857, 17406952.
6. Macintyre CR, Goebel K, Brown GV. Patient knows best: blinded assessment of nonadherence with antituberculous therapy by physicians, nurses, and patients compared with urine drug levels. Prev Med 2005, 40(1):41-45. 10.1016/j.ypmed.2004.04.045, 15530579.
7. Persaud R. Both sides need to keep the relationship going. Br Med J 2003, 326:1337.
8. Dartnell JGA, Anderson RP, Chohan V, Galbraith KJ, Lyon MEH, Nestor PJ, Moulds FW. Hospitalization for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 1996, 164:659-662.
9. Psaty BM, Koepsell TD, Wagner EH, Lo Gerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of B-blockers. JAMA 1990, 263(12):1653-1657. 10.1001/jama.1990.03440120075040, 1968518.
10. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995, 21(3):419-429. 10.1093/schbul/21.3.419, 7481573.
11. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004, 27:2149-2153. 10.2337/diacare.27.9.2149, 15333476.
12. Trueman P, Lowson K, Blighe A, Meszaros A, Wright D, Glanville J, Taylor D, Newbould J, Bury M, Barber N, et al. Evaluation of the Scale, Causes and Costs of Waste Medicines 2010, London: YHEC/School of Pharmacy.
13. Sinclair HK, Bond CM, Stead LF. Community pharmacy personnel interventions for smoking cessation. Cochrane Database Syst Rev 2004, 1. CD003698.
14. Horgan JMP, Blenkinsopp A, McManus RJ. Evaluation of a cardiovascular disease opportunistic risk assessment pilot ('Heart MOT' service) in community pharmacies. J Public Health 2010, 32:110-116.
15. Blenkinsopp A, Phelan M, Bourne J, Dakhil N. Extended adherence support by community pharmacists for patients with hypertension: a randomized controlled trial. Int J Pharm Pract 2000, 8:165-175.
16. George J, Elliott RA, Stewart DC. A systematic review of interventions to improve medication taking in elderly patients prescribed multiple medications. Drugs Aging 2008, 25(4):307-324. 10.2165/00002512-200825040-00004, 18361541.
17. Murray MD, Young JM, Morrow DG, Weiner M, Tu W, Hoke SC, Clark DO, Stroupe KT, Wu J, Deer MM, et al. Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure. Am J Geriatric Pharmacother 2004, 2(1):53-65.
18. Taylor SJ, Milanova T, Hourihan F, Krass I, Coleman C, Armour CL. A cost-effectiveness analysis of a community pharmacist-initiated disease state management service for type 2 diabetes mellitus. Int J Pharm Pract 2005, 13:33-40.
19. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Boyd M, Cresswell K, Eden M, Elliott RA, Franklin M, Hippisley-Cox J, et al. Patient safety research portfolio. PINCER trial: A Cluster Randomized Trial Comparing the Effectiveness and Cost-effectiveness of a Pharmacist-led IT-based Intervention with Simple Feedback in Reducing Rates of Clinically Important Errors in Medicines Management in General Practices 2010, Birmingham: Department of Health.
20. Bond CM, Fish A, Porteous TH, Reid JP, Scott A, Antonazzo E. A randomized controlled trial of the effects of note-based medication review by community pharmacists on prescribing of cardiovascular drugs in general practice. Int J Pharm Pract 2007, 15:39-46.
21. Bond C. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Pract 2007, 24(2):189-200.
22. Holland R, Lenaghan E, Harvey I, Smith R, Shepstone L, Lipp A, Christou M, Evans D, Hand C. Does home based medication review keep older people out of hospital? The HOMER randomized controlled trial. BMJ: Br Med J 2005, 330(7486):293-295.
23. Holland R, Brooksby I, Lenaghan E, Ashton K, Hay L, Smith R, Shepstone L, Lipp A, Daly C, Howe A, et al. Effectiveness of visits from community pharmacists for patients with heart failure: HeartMed randomized controlled trial. Br Med J 2007, 334(7603):1098-1104.
24. Blenkinsopp A, Hassey A. Effectiveness and acceptability of community pharmacy-based interventions in type 2 diabetes: a critical review of intervention design, pharmacist and patient perspectives. Int J Pharm Pract 2005, 13(4):231-240.
25. Hay EM, Foster NE, Thomas E, Peat G, Phelan M, Yates HE, Blenkinsopp A, Sim J. Effectiveness of community physiotherapy and enhanced pharmacy review for knee pain in people aged over 55 presenting to primary care: pragmatic randomized trial. Br Med J 2006, 333:995-998.
26. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, Bero L. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev 2010, 7. CD000336.
27. Edmunds J, Calnan M. The reprofessionalization of community pharmacy? An exploration of attitudes to extended roles for community pharmacists amongst pharmacists and general practitioners in the United Kingdom. Soc Sci Med 2001, 53:943-955. 10.1016/S0277-9536(00)00393-2, 11522139.
28. De Rijdt T, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm 2008, 65(12):1161-1172. 10.2146/ajhp070506, 18541687.
29. Pacini M, Smith RD, Wilson ECF, Holland R. Home-based medication review in older people: is it cost effective?. Pharmacoeconomics 2007, 25(2):171-180. 10.2165/00019053-200725020-00008, 17249858.
30. Respect Trial Team Cost-effectiveness of shared pharmaceutical care for older patients: RESPECT trial findings. Br J Gen Pract 2010, 60(570):e20-e27. 2801802, 20040164, Respect Trial Team.
31. Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005, 39:508-515. 10.1345/aph.1E398, 15657115.
32. Horne R, Barber N, Weinman J, Elliott RA, Morgan M, Cribb A. Study report. Concordance, Adherence and Compliance in Medicine Taking: A Scoping Exercise 2006, London: NIHR Service Delivery and Organization.
33. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence (Review). Cochrane Database Syst Rev 2008, 2: .
34. National Institute for Health and Clinical Excellence Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical Guidelines: CG76 2009, London: HMSO, National Institute for Health and Clinical Excellence.
35. Elliott RA. Strategies for improving poor adherence to medication to optimize rheumatoid arthritis disease management. Dis Manage Health Outcomes 2008, 16:13-29.
36. Elliott R. Non-adherence to medicines: not solved but solvable. J Health Serv Res Policy 2009, 14(1):58-61. 10.1258/jhsrp.2008.008088, 19103918.
37. Elliott RA. Poor adherence to anti-inflammatory medication in asthma: reasons, challenges, and strategies for improved disease management. Dis Manage Health Outcomes 2006, 14(4):223-233.
38. Blenkinsopp A, Bond CM. The potential and pitfalls of medicine management: what have we learned so far?. Dis Manage Health Outcomes 2008, 16:79-86.
39. Blenkinsopp A, Celino G, Bond C, Inch J. Medicines use reviews: the first year of a new community pharmacy service. Pharm J 2007, 278:218-223.
40. Blenkinsopp A, Bond C, Celino G, Inch J, Gray N. Medicines use review: adoption and spread of a service innovation. Int J Pharm Pract 2008, 16:271-276.
41. Bradley F, Wagner AC, Elvey R, Noyce PR, Ashcroft DM. Determinants of the uptake of medicines use reviews (MURs) by community pharmacies in England: a multi-method study. Health Policy 2008, 88:258-268. 10.1016/j.healthpol.2008.03.013, 18468713.
42. Krska J, Avery AJ. Evaluation of medication reviews conducted by community pharmacists: A quantitative analysis of documented issues and recommendations. Br J Clin Pharmacol 2008, 65:386-395. 10.1111/j.1365-2125.2007.03022.x, 2291260, 17922887.
43. MacAdam AB, Sherwood J. An investigation into the provision of Medicines Use Reviews (MURs) by community pharmacists within Brighton and Hove Primary Care Trust. International Journal of Pharmacy Practice 2011, (Conference start: 5 May 2011, Conference end: 6 May 2011) 2011, United Kingdom: Health Services Research and Pharmacy Practice Conference Norwich United Kingdom.
44. Khideja N. Community pharmacists' experience and perceptions of Medicines Use Review: initial and ongoing training of community pharmacists in the Black Country region - West Midlands. International Journal of Pharmacy Practice 2009, (Conference start: 6 September 2009, Conference end: 9 September 2009) 2009, Manchester United Kingdom: British Pharmaceutical Conference.
45. New Medicines Service http://psnc.org.uk/services-commissioning/advanced-services/nms/.
46. Barry CA, Stevenson F, Britten N, Barber N, Bradley C. Giving voice to the lifeworld. More humane, more effective medical care? A qualitative study of doctor-patient communication in general practice. Soc Sci Med 2001, 53:487-505. 10.1016/S0277-9536(00)00351-8, 11459399.
47. Barry CA, Bradley C, Britten N, Stevenson F, Barber N. Patients' unvoiced agendas in general practice consultations. Br Med J 2000, 320:1246-1250.
48. Stevenson F, Barry CA, Britten N, Barber N, Bradley C. Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med 2000, 50:829-840. 10.1016/S0277-9536(99)00376-7, 10695980.
49. Britten N, Stevenson F, Barry CA, Barber N, Bradley C. Misunderstandings in general practice prescribing decisions: a qualitative study. Br Med J 2000, 320:484-488.
50. Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients' problems with new medication for chronic conditions. Qual Saf Health Care 2004, 13(3):172-175. 10.1136/qshc.2003.005926, 1743839, 15175485.
51. Clifford S, Barber N, Elliott R, Hartley E, Horne R. Patient-centered advice is effective in improving adherence to medicines. Pharm World Sci 2006, 28(3):165-170. 10.1007/s11096-006-9026-6, 17004019.
52. Elliott RA, Clifford S, Barber N, Hartley E, Horne R. The cost effectiveness of a pharmacy advisory service to improve adherence to medicines. Pharm World Sci 2008, 30:17-23.
53. Hawe E, Yuen P, Baillie L. OHE Guide to UK Health and Health Care Statistics 2011, London: Office of Health Economics.
54. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: A review of published literature and international experience. Br J Clin Pharmacol 2007, 63:148-156. 10.1111/j.1365-2125.2006.02746.x, 2000570, 17274788.
55. Clifford S. Non-adherence: An Exploration of Its Causes and an Evaluation of an Intervention 2004, University of London: School of Pharmacy.
56. Pharmaceutical Services Negotiating Committee, NHS Employers NHS Community Pharmacy Contractual Framework 2011/12 Service Developments - Latest Information 2011, London: PSNC, Pharmaceutical Services Negotiating Committee, NHS Employers.
57. Clifford S. Evaluation of a patient-centered, pharmacist-delivered intervention to improve patients' adherence to medication. Psychol Health 2005, 20:48-49.
58. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002, 288:2880-2883. 10.1001/jama.288.22.2880, 12472330.
59. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008, 10:348-354.
60. Netten A, Dennett J. Unit Costs of Community Care 2007 2007, Kent, Canterbury: Personal Social Services Research Unit.
61. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomized controlled trials. BMJ 1999, 319(7211):670-674. 10.1136/bmj.319.7211.670, 28218, 10480822.
62. Shih WJ. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 2002, 3(1):4. 10.1186/1468-6708-3-4, 134476, 11985778.
63. StataCorp LP Stata Data Analysis and Statistical Software. Special Edition Release 10.1 Edition 2008, Texas: Stata: College Station, StataCorp LP.
64. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998, 3(4):233-245.
65. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000, 355(9209):1064-1069. 10.1016/S0140-6736(00)02039-0, 10744093.
66. Drummond M, MJ S, Torrance G, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programs 2005, Oxford: Oxford University Press, 3.
67. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000, 19:3219-3236. 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P, 11113956.
68. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005, 187(2):106-108. 10.1192/bjp.187.2.106, 16055820.
69. Fenwick E, Claxton K, Sculpher MJ. Representing uncertainty: the role of cost effectiveness acceptability curves. Health Econ 2001, 10:779-787. 10.1002/hec.635, 11747057.
70. Frazier SK, Moser DK, Daley LK, McKinley S, Reigel B, Garvin BJ, An K. Critical care nurses' beliefs about and reported management of anxiety. Am J Crit Care 2003, 12(1):19-27.
71. O'Brien B, Briggs A. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res 2002, 11(6):455-468. 10.1191/0962280202sm304ra, 12516984.
72. Dowie J. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant. Health Econ 2004, 13(5):453-459. 10.1002/hec.861, 15127425.
73. Ziebland S, McPherson A. Making sense of qualitative data analysis: an introduction with illustrations from DIPEx (personal experiences of health and illness). Med Educ 2006, 40:405-414. 10.1111/j.1365-2929.2006.02467.x, 16635119.
74. Dean B, Schachter M, Vincent C, Barber N. Causes of prescribing errors in hospital inpatients: a prospective study. Lancet 2002, 359(9315):1373-1378. 10.1016/S0140-6736(02)08350-2, 11978334.
75. Russell CL. Culturally responsive interventions to enhance immunosuppressive medication adherence in older African American kidney transplant recipients. Prog Transplant 2006, 16(3):187-196.